[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"skin-cancer-melanoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:skin-cancer-melanoma":70},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":25,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100613404",false,"NCT07266142","Prospective Collection of Clinical Data and Human Body Material (HBM) of Cutaneous Melanoma, Non Melanoma Patients and Healthy Controls. Biobank Huidkanker","Prospective Collection of Clinical Data and Human Body Material (HBM): Blood (Serum, Plasma, DNA) and Tissue of Cutaneous Melanoma, Non Melanoma Patients and Healthy Controls. Biobank Huidkanker","Inclusion Criteria:\n\n* Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures\n* Adult subjects (\\>18 years of age) at time of enrolment.\n* Subjects diagnosed with cutaneous melanoma, Non-melanoma skin cancer or healthy controls.\n* Adult subjects able and willing to provide informed consent.\n\nExclusion Criteria:\n\n* Subjects unable or not willing to provide informed consent.\n* Pregnancy (or willing to become pregnant) is NOT an exclusion criteria (unless specified in the respective satellite protocols.","ALL","18 Years",{"count":18,"type":19},7500,"ESTIMATED","OBSERVATIONAL","The goal of this clinical trial is to set up a prospective, fit-for-purpose collection of human body material (HBM)-blood (serum, plasma, DNA) and tissue-and standardized clinical data of patients with cutaneous melanoma, non-melanoma skin cancer and healthy controls.\n\nThe main questions it aims to answer are:\n\n* To create a biobank with samples of human body material (HBM): blood (serum\u002Fplasma\u002FDNA) and tissue and clinical data of patients with cutaneous melanoma, non-melanoma and helathy controls.\n* To support future research questions (after specific approval of the Ethics Committee) by using the biobank (through satellite protocols).\n\nIf there is a comparison group: Not applicable (umbrella protocol for collection only).\n\nParticipants will:\n\n* Share demographics, medical and surgical history, risk factors.\n* Complete Cancer Worry Scale questionnaire.\n* Provide biological samples:\n\n  * Blood samples (serum, plasma, DNA).\n  * Tissue samples (residual tissue or additional biopsy if consented).",[23,24],"Skin Cancer, Non-Melanoma","Skin Cancer Melanoma",[26,27,28],"Prospective Collection","Skin Cancer","Human Body Material","RECRUITING","2026-06-10",{"date":32,"type":33},"2026-06-12","ACTUAL",{"date":35,"type":33},"2025-11-17",{"date":37,"type":19},"2051-01",{"name":39,"class":40},"Universitaire Ziekenhuizen KU Leuven","OTHER",1,{"id":43,"slug":4,"hasResults":10,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":27,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":15,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":51,"studyType":20,"phases":4,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":41},"100604037","NCT07144306","AI-Driven Early Detection of Skin Cancer","Inclusion Criteria:\n\nAdults (≥18 years) presenting with skin lesions suspicious for malignancy.\n\nAbility to provide informed consent.\n\nExclusion Criteria:\n\nInability to provide informed consent.\n\nPoor-quality images unsuitable for AI analysis.",true,"18 Months",{"count":50,"type":19},100,"50 Months","This study evaluates the feasibility and accuracy of an AI-powered mobile platform (NuvanaDx) for early detection of skin cancer, including melanoma, using smartphone-based imaging. The platform is designed to improve access to early diagnosis, reduce waiting times, and support triage into appropriate care pathways.",[24],[27,55,56,57,58,59],"Melanoma","Early Detection","Artificial Intelligence","Dermatology","Digital Health","2025-09-25",{"date":62,"type":33},"2025-09-26",{"date":64,"type":19},"2025-10-01",{"date":66,"type":19},"2026-01-01",{"name":68,"class":69},"Nuvana Healthcare LTD","INDUSTRY",""]